Cogstate (ASX:CGS): Clinical Trial Contracts and Cognitive Testing Demand

Aditi Sarkar

30 October 2026 08:16 PM AEDT

Cogstate (ASX:CGS): Clinical Trial Contracts and Cognitive Testing Demand

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Cogstate supplies digital cognitive assessments and clinical-trial endpoint services.
Net sales contracts signed during 1QFY27 totalled US$25.1 million.
Contracted FY27 revenue was US$56.8 million at 30 September 2026.
Its FY26 report recorded revenue of approximately US$60.9 million.

Cogstate Limited provides cognitive assessment technologies and clinical-trial data services, particularly for studies involving the central nervous system. Its October business update described new sales contracts, committed future work and the timing of expected revenue recognition across research programs.

Clinical Trials and the September Quarter

For the quarter ended 30 September 2026, Cogstate (ASX:CGS) reported US$25.1 million of net sales contracts executed, compared with US$21.42 million in the corresponding quarter. The figure describes contracts signed during 1QFY27 rather than revenue recognised in the same three months. Management also highlighted five Phase 3 studies involving bipolar disorder or depression across two customers.

Contracted Revenue and Delivery Timing

The company stated that the five Phase 3 trials accounted for more than 80% of the quarter’s total contract sales value. The high concentration makes the duration and implementation of these trials relevant when interpreting the sales figure. Longer clinical studies can generate revenue over extended periods as milestones are delivered rather than at contract signature.

Cogstate (ASX:CGS) reported contracted FY27 revenue of US$56.8 million at 30 September 2026, up from US$48.3 million at 30 June 2026. It also reported an overall contracted revenue position, including certain revenue already recognised in the quarter, of US$143.7 million. The update separated work scheduled for FY27 from later periods, rather than presenting a single near-term revenue forecast.

Annual Results and Revenue Recognition

Cogstate’s FY26 annual report recorded revenue of US$60.9 million, compared with US$53.1 million for FY25. It reported EBITDA of US$18.3 million and net profit after tax of approximately US$11.9 million. The results are historical operating outcomes, while contracts executed in September 2026 relate to the subsequent financial year.

Cogstate (ASX:CGS) noted that the first-quarter in-year revenue yield from newly executed contracts was 34%, reflecting a lower licence fee component and the length of some Phase 3 programs. Its business model therefore requires distinctions between contract wins, contracted backlog and revenue recognised in the financial statements. The October announcement specifically described these timing differences.

The first-quarter update also explained that licence fees represented 7% of contract sales, below a historical range of 20%–25%. Cogstate (ASX:CGS) linked the difference to the mix of longer-duration Phase 3 trials. That reported mix helps explain why additions to contracted revenue for later years may be larger than additions scheduled for the current financial year.

Contracted revenue has its own timing profile. Cogstate explained that clinical-trial agreements may run from relatively short early-stage studies to multi-year Phase 3 programs, with revenue recognised when predetermined milestones are achieved. This means that the quarter in which a contract is executed and the period in which its value appears in reported revenue can differ. Cogstate (ASX:CGS) specifically disclosed the projected allocation of its contracted work across financial years. The reporting distinction is essential when comparing September-quarter contract signings with audited FY26 revenue and profit. It also helps explain why reported contract values should not be treated as immediate cash receipts or completed clinical trial deliveries.

Key Insights

Cogstate (ASX:CGS) entered FY27 with new clinical-trial contract signings and a larger contracted revenue position than at the preceding June year-end. Its 2026 disclosures provide both completed financial results and forward-looking contract coverage. The conversion of signed studies into recognised revenue depends on work performed and contractual milestones.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.